Project overview
This six-year study at Kidwai Memorial Institute of Oncology evaluated the prognostic value of the 2023 WHO grading system for epithelioid mesothelioma. Among 27 cases of mesothelioma, 21 were epithelioid and graded using nuclear atypia, mitotic count, and necrosis criteria. Most tumors (90.5%) were low grade, while two were high grade. High-grade tumors showed significantly poorer survival, supporting the new grading framework’s prognostic accuracy. The pleura was the most frequent site, and the mean patient age was 52 years. Histopathological grading correlated well with patient outcomes, reinforcing the clinical relevance of this refined classification. The study emphasizes the importance of standardized grading for better risk stratification and personalized treatment. Implementation of WHO 2023 guidelines in pathology practice can enhance prognostication and inform therapeutic decisions for this aggressive malignancy.
This summary describes the research topic in our project library. Research findings belong to the authors; they are not outcomes of editorial support. Authors retain responsibility for their work.
Back to this project’s library page